On World No Tobacco Day experts flag concerns about illegal promotion of new-age gateway devices endangering adolescents and the youth
In the event, Dr Avinash Sunthlia – Deputy Additional Director General (DADG), Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India said 'Why is the industry using new tactics to attract our youth? Because the industry needs new users to consume these new devices so that they can be turned into lifelong consumers. Hence, despite the ban on these products through the Prohibition of Electronic Cigarettes Act (PECA), 2019, producers have found ways to circumvent the laws and promote e-cigarettes and vapes. They also market these devices as safer alternatives for smoking cessation, but it is about recruiting new users for a lifetime of dependence,'
'To spread awareness we have issued comprehensive guidelines for schools, initiated capacity-building programmes for teachers, and are working closely with influencers and digital creators to speak up about the dangers of vaping. We've also launched an online reporting platform that empowers everyday citizens to flag violations related to the sale or promotion of these banned devices so that prompt action can be taken. I'd like to extend my heartfelt appreciation to Mothers Against Vaping for their unwavering commitment and advocacy on this critical issue', added Dr. Sunthlia.
The seminar was organised at the Indian International Centre, New Delhi by Mothers Against Vaping, a united front of concerned mothers combating the escalating vaping crisis among our youth. In the event, various experts put the spotlight on the role of promotions in targeting a new generation of young users through new-age gateway devices even as Mothers Against Vaping released a report titled 'Unmasking the Appeal – How Vapes & E-Cigarettes Continue to be Promoted Unabated in India'.
Jaspal Singh, Special Commissioner of Police for Protective Security, Delhi, in his keynote address, said, 'Vapes are more dangerous than cigarettes because through such devices, one can even consume hard drugs. Based on my experience, several users have confessed to using vaping equipment for hard drug intake. What makes the threat more dangerous is the way these products are promoted. Manufacturers and sellers use tactics like influencer marketing on social media to glamorise these devices and target young users while avoiding direct accountability and prosecution.'
'There has to be a proper coordination between customs authorities, police authorities, transporter associations and even courier agencies to stem the rising tide of e-cigarettes and vapes. Also important is public involvement, but for that to happen, citizens need to be aware that these devices are banned in India. Therefore, it is critical that the government launch strong awareness campaigns to inform people about the illegality and dangers of these devices", added Singh
Padma Jaiswal - IAS, Secretary to the Government of the Union Territory of Puducherry, said, 'I would really like to acknowledge the great effort done by Mothers Against Vaping. I believe that such a kind of initiative and prioritisation has not been done by any civil society organisation earlier towards generating awareness of the issue.'
'The government has made the law banning vaping and e-cigarettes because it has seen from its own data that most of the users who are being affected by vaping are the adolescents who are in the schools and colleges. Being a mother myself, I am aware that vaping is rampant and the habit leaves a strong impact among the adolescents and the youth. They are attracted to these devices because they are promoted as a luxury, a style statement with the narrative that it is neither harmful nor punitive. Therefore, we need to raise the awareness that these electronic devices are banned in India,' Ms Jaiswal added.
On the occasion, Mothers Against Vaping also released investigative report exposing the alleged covert strategies employed by global vaping and e-cigarette brands to infiltrate India's digital landscape, circumventing the Prohibition of Electronic Cigarettes Act (PECA) of 2019. Despite the ban, these entities exploit media loopholes, leveraging digital platforms, influencer marketing, and surrogate advertising to glamorise their products .
The comprehensive analysis reveals a disturbing trend: the deliberate targeting of Indian youth through social media channels. Platforms like Instagram and Facebook are inundated with content portraying vaping as a trendy, harmless lifestyle choice. Influencers, often with substantial followings, are co-opted to promote these products, masking their dangers under the guise of modernity and sophistication. Influencers have emerged as stealth marketers—turning reels, reviews, and jokes into powerful tools of vape promotion. From casual endorsements masked as lifestyle content to creative smoke tricks that mimic skill, the influencer ecosystem plays a crucial role in making vaping look aspirational, trendy, and even humorous.
Despite the ban, India's digital and informal markets continue to thrive in brazen defiance of the ban. Hence, the report provides for a number of recommendations as below:
Immediate Actions To Stop Promotion of Vapes and E-Cigarettes Coordinate Enforcement Efforts: Establish robust coordination between cybercrime units, law enforcement agencies, and regulatory bodies to proactively monitor and identify violative digital content and actors. Initiate Legal Proceedings against Violators: Launch immediate legal action under relevant provisions of the Prohibition of Electronic Cigarettes Act, 2019 (PECA) and other applicable laws. Dismantle Digital Channels: Identify and issue directives for taking down social media pages, handles, and websites that promote vapes. Issue Platform Wide Directives: Direct social media companies, technology platforms and digital marketplaces, including domain service providers, to comply with Indian law by proactively detecting and preventing promotion of these banned products. Initiate action against Manufacturers and Sources: Pursue action against manufacturers, importers, and distributors who make these dangerous products available for sale.
Recommendations from the report:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
7 hours ago
- News18
WHO calls for research scale-up towards ending TB in South-East Asia region
New Delhi, Aug 5 (PTI) The WHO on Tuesday called for urgent scale-up of research, innovation and collaboration to accelerate momentum towards ending tuberculosis in the South-East Asia region, which continues to bear nearly half of the global TB burden, accounting for the highest share of cases and deaths worldwide. Experts, national TB programme managers and researchers along with partners and members of civil society began a three-day virtual workshop organised by the World Health Organization (WHO) for advancing research and innovation to accelerate momentum towards ending TB in the WHO South-East Asia region. 'In our Region alone, nearly 5 million people developed TB and close to 600,000 died from the disease in 2023," said Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia Region. Calling for urgent action, she said that achieving the ambitious targets in the WHO End TB Strategy requires collaboration to accelerate research and innovation. It requires the adoption and use of new tools, technologies and drugs. Ensuring timely and equitable access to these innovations remains critical to achieving impacts at scale, leaving no one behind, Boehme said. While the region recorded a significant increase in TB case notifications in 2023, signalling recovery after COVID-19-related setbacks, progress remains insufficient to meet the End TB Strategy targets aligned with the sustainable development goals that call for a 90 per cent reduction in TB deaths and an 80 per cent reduction in incidence by 2030 compared to 2015 levels. Post-COVID-19 pandemic, TB once again reemerged as the world's leading cause of death from a single infectious agent, the WHO said in a statement. It places a disproportionate burden on the poorest and most vulnerable, further exacerbating inequalities. In the South-East Asia region, 30 per cent to 80 per cent of the TB-affected households experience catastrophic costs, underscoring the need for equitable, people-centred approaches and strengthening social protection for the affected, the statement said. Despite these challenges, the WHO South-East Asia region made notable progress. In 2023, 3.8 million new and relapse TB cases were notified, with an 89 per cent treatment success rate for those who began treatment in 2022. Missed cases dropped to 22 per cent in 2023, down from 44 per cent in 2020, the statement said. Backed by strong political commitment, countries in the region are increasingly leveraging new approaches such as artificial intelligence for case detection, computer-aided diagnostics, digital adherence tools and direct benefit transfers for patients, streamlining the social support process. At the same time, several countries are undertaking important research, including epidemiological research to assess the disease burden, the statement said. Bangladesh recently completed a patient cost survey, while findings from India's RATIONS study on the impact of nutrition on TB outcomes and incidence of the disease have contributed to the global guidance. Social and community-based innovations are also playing a vital role. Nepal's TB-Free Pallika initiative and multisectoral coordination mechanisms in Myanmar are helping reach vulnerable populations with person-centred care. A review by the WHO South-East Asia found that member states published over 3,000 TB-related research articles in the past six years, with 60 per cent being original research. However, uptake of research outcomes remains uneven due to knowledge gaps and limited platforms for knowledge exchange and collaborative use, the statement said. 'Our progress is uneven. Research and innovation capacity is varied across the Region, and the results of these efforts are often siloed and unavailable for collaborative use. The rise in drug-resistant forms of TB remains very concerning," said Dr Boehme. The key areas of focus during the virtual consultation include strengthening of South-South collaboration, vaccine preparedness, digital tools for patient care and adherence and efforts to overcome vaccine hesitancy. Participants will also discuss aligning regulatory processes, promoting data sharing and improving platforms for knowledge exchange. A significant emphasis is being placed on identifying operational implementation research priorities, especially in relation to social determinants such as undernutrition and climate change, which influence TB incidence and outcomes. top videos View all 'Several ongoing innovations are attempting to reach out to marginalized and vulnerable groups through active case finding and providing affected families socio-economic support to mitigate catastrophic costs", said Dr Boehme. Highlighting the importance of equity, she added, 'It is incumbent to ensure equitable access to the benefits of research and innovation, including vaccines, medicines and diagnostics." PTI PLB KSS KSS (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 05, 2025, 19:30 IST News agency-feeds WHO calls for research scale-up towards ending TB in South-East Asia region Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hindustan Times
7 hours ago
- Hindustan Times
Early immunisation critical in preventing RSV in infants
Respiratory illnesses in newborns are a major cause of concern, especially when they involve difficulty in breathing. Among the leading causes is Respiratory Syncytial Virus (RSV), a common and highly severe virus that affects the lungs and airways of infants and children under five. This virus often mimics symptoms of a common cold, such as a runny nose or low-grade fever. This similarity can create confusion for parents and health care providers alike, leading to delays in detection and intervention, which allows the illness to rapidly escalate. Vaccination (Getty Images/iStockphoto) For newborns and infants, whose immune systems are still developing, and airways are small, RSV can quickly become serious. Their tiny airways can get easily blocked by swelling and mucus, leading to lung infections like bronchiolitis or pneumonia. Each year, RSV leads to over 3.6 million hospitalisations and about 100 000 deaths in children under five years of age. As per WHO, most paediatric RSV deaths (97%) occur in low- and middle-income countries where there is limited access to supportive medical care. Even healthy, full-term babies can face complications, and in some cases, require intensive medical care. In India, RSV cases spike during the monsoon and early winter, but the virus can circulate throughout the year. This makes timely protection critical. Medical advancements now offer a way to shield infants through immunisation strategies. While the RSVpreF maternal vaccine is not yet available in India, two monoclonal antibodies have emerged as key preventive options in India. Palivizumab, is administered monthly to high-risk infants such as those born prematurely or with underlying heart or lung conditions. Nirsevimab, on the other hand, is a long-acting monoclonal antibody offering protection with a single-dose. It is designed for all infants regardless of risk category and can be administered soon after birth, before hospital discharge, or during early routine check-ups. Early immunization plays a vital role in protecting infants not just from immediate illness, but also from long-term respiratory complications. Severe RSV infections in the first year of life have been linked to increased risk of recurrent wheezing, asthma, ear infections, and reduced lung function well into adolescence. Infants are especially vulnerable because their immune systems are still developing, and their smaller airways are more easily blocked by inflammation caused by the virus. By providing protection before exposure, through timely use of preventive monoclonal antibodies, we are better equipped to avoid serious outcomes for babies. Parents must understand the importance of stopping the virus before it can take hold, reducing the likelihood of hospitalisation and long-term health issues. For parents and health care providers alike, early immunisation isn't just a seasonal precaution, it's a critical investment in the child's long-term respiratory health and overall well-being. This article is authored by Dr Faisal B Nahdi, paediatrician, Rainbow Children's Hospital, Hyderabad.
Hindustan Times
7 hours ago
- Hindustan Times
What are chikungunya symptoms? CDC issues travel warning for China amid outbreak
Americans travelling to China have been advised to practice utmost caution in the wake of the chikungunya virus outbreak in the country. A Level 2 travel alert was issued by the US Centers for Disease Control and Prevention (CDC) in this regard last week. CDC issued warning for Americans traveling to China after the Chikungunya outbreak.(Unsplash) This comes as more than 7,000 cases of the mosquito-borne virus were reported in the Guangdong province of China, forcing the authorities to put in measures similar to the ones taken during the COVID-19 pandemic period, as per BBC. Among the worst-affected regions in the country is the city of Foshan, where chikungunya patients have been ordered to stay in the hospital until they test negative. They will be discharged at the end of a week-long stay, and their beds are being protected using mosquito nets. Chikungunya: What to know? The viral disease is transmitted mainly through the Aedes mosquitoes. It is caused by the chikungunya virus (CHIKV), which is an RNA virus in the alphavirus genus of the Togaviridae family, as per the World Health Organization (WHO). CHIKV was identified for the first time in the United Republic of Tanzania in 1952, while major outbreaks have been reported in America, Asia, and Africa. A study that came out in Nature in June this year, estimated that around 35.3 million people get infected by Chikungunya on an annual basis across 180 countries and regions. It leads to nearly 3,700 deaths, which is 0.01% of the total cases, as per TIME magazine. The latest outbreak in China has been attributed to imported cases. Liu Qiyong, China CDC's chief expert in vector-borne disease control, told CGTN, 'With the virus spreading globally, imported cases have inevitably reached China.' Chikungunya symptoms The WHO states that chikungunya symptoms are quite similar to dengue and Zika, thus making it difficult to diagnose the disease and accurately determine the total number of infected persons. Also read: Chikungunya outbreak: China on high alert as Guangdong battles over 7,000 cases amid COVID like strict measures Some of the most common symptoms of Chikungunya include high fever, joint pain, headache, muscle pain, as well as joint swelling and rashes. The symptoms usually appear around 4-8 days after the patient is bitten by the infected mosquito. At first, the person gets to witness an 'abrupt onset of fever, frequently accompanied by severe joint pain,' as per the WHO. Notably, the joint pain is often debilitating and can last anywhere from a few days to weeks, months, and even years in some cases. While most of the patients completely recover from the infection, there are cases of eye, heart, and neurological complications that have come up due to the CHIKV infection. FAQs: 1. Why CDC has issued a warning for China? CDC's Level 2 alert, which is designated as 'Practice Enhanced Precautions', came out after China marked over 7,000 cases of chikungunya infections. 2. How are chikungunya patients treated? No specific antiviral treatment is available for the chikungunya virus infections. Usually, doctors give antipyretic and analgesic medications, like paracetamol, for fever and pain, as per the WHO. Also, there are two chikungunya vaccines that have received regulatory approvals, but these are not widely available. 3. Is chikungunya fatal? Severe symptoms and deaths from the viral disease are rare, occurring mostly among young children or elderly people who have co-existing health problems.
